Last reviewed · How we verify
HCV treatment
HCV treatment is a Small molecule drug developed by ANRS, Emerging Infectious Diseases. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | HCV treatment |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (PHASE1)
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (PHASE4)
- Digital Community to Improve Health in Rural Areas (NA)
- KP-Led Same Day HCV Test and Treat Study (NA)
- Appalachian Partnership to Reduce Disparities (Aim 2) (NA)
- Advanced Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants (NA)
- Implementing Low-Barrier HCV Treatment in a Jail Setting (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HCV treatment CI brief — competitive landscape report
- HCV treatment updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI
Frequently asked questions about HCV treatment
What is HCV treatment?
Who makes HCV treatment?
What development phase is HCV treatment in?
Related
- Manufacturer: ANRS, Emerging Infectious Diseases — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing